Serum Cystatin C as an Indicator of Renal Function and Mortality in Liver Transplant Recipients

Alina M. Allen, W. Ray Kim, Joseph J. Larson, Colin Colby, Terry M. Therneau, Andrew D. Rule

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Chronic kidney disease (CKD) is an important comorbidity after liver transplantation (LT); however, reliable tools with which to evaluate these patients are limited. In this work, we examine the extent to which the addition of serum cystatin C improves glomerular filtration rate (GFR) estimation and mortality prediction, in comparison to various GFR-estimating equations. Methods The GFR was measured in LT recipients by iothalamate clearance. Concurrent serum cystatin C was assayed in banked serum samples. Performance of GFR-estimating equations with and without cystatin C, including the modification of diet in renal disease and CKD-epidemiology collaboration formulas was assessed. The proportional hazards regression analysis was performed to determine the association between serum cystatin C and mortality. Results A total of 586 iothalamate results were obtained in 401 patients after a mean of 4 years after LT. When compared to measured GFR, the formula with both creatinine and cystatin C, namely, CKD-epidemiology cr-cys, outperformed those with either marker alone. Performance of creatinine-based models was similar to one another. Serum cystatin C, by itself or as a part of an estimated GFR, was a significant predictor of mortality. Conclusions Serum cystatin C has an important role in enhancing accuracy of GFR estimation and predicting mortality in LT recipients.

Original languageEnglish (US)
Pages (from-to)1431-1435
Number of pages5
Issue number7
StatePublished - Jul 2 2015

ASJC Scopus subject areas

  • Transplantation


Dive into the research topics of 'Serum Cystatin C as an Indicator of Renal Function and Mortality in Liver Transplant Recipients'. Together they form a unique fingerprint.

Cite this